Nature Search

Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown

This virus-free approach for mRNA knockdown in vivo uses the siRNA carrier peptide protamine, chemically coupled to a cell surface receptor internalizing antibodies via sulfo-SMCC, to provide protection and guidance for the targeted application of siRNA.

Nicole Bäumer
Neele Appel
Sebastian Bäumer
Protocols03 Dec 2015
Nature Protocols

Volume: 11, P: 22-36
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response

Müller-Tidow and colleagues demonstrate that hotspot DNMT3A mutations found in clonal hematopoiesis and acute myeloid leukemia render cancer cells sensitive to the DNMT1 inhibitor azacitidine through focal DNA demethylation, viral mimicry and interferon activation.

Marina Scheller
Anne Kathrin Ludwig
Carsten Müller-Tidow
Research25 May 2021
Nature Cancer

Volume: 2, P: 527-544
AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia

Zhou et al. show that in the context of AML1-ETO-driven leukaemia, AES and DDX21 induce small nucleolar RNA (snoRNA)–ribonucleoprotein (RNP) formation and this is important for self-renewal of leukaemic cells.

Fengbiao Zhou
Yi Liu
Carsten Müller-Tidow
Research26 Jun 2017
Nature Cell Biology

Volume: 19, P: 844-855
Targeted siRNA nanocarrier: a platform technology for cancer treatment

Nicole Bäumer
Jessica Tiemann
Sebastian Bäumer
ResearchOpen Access26 Feb 2022
Oncogene

Volume: 41, P: 2210-2224
Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells

Ping Ji
Shuchi Agrawal
Carsten Müller-Tidow
Research27 Dec 2004
Oncogene

Volume: 24, P: 2739-2744

Quick links

Search

Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown

Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia

Targeted siRNA nanocarrier: a platform technology for cancer treatment

Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells

Search

Quick links

Search

Filter By:

Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown

Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia

Targeted siRNA nanocarrier: a platform technology for cancer treatment

Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells

Search

Quick links